Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence C Newman

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Neurology|October 26, 2005
Reversible anorgasmia with topiramate therapy for migraineLawrence C Newman, Susan W Broner, Christine L Lay
Headache|June 9, 2011
Migraine and vestibular symptoms--identifying clinical features that predict "vestibular migraine"Joshua M Cohen, Marcelo E Bigal, Lawrence C Newman
Journal of Women'S Health (2002)|July 25, 2009
Frovatriptan for acute treatment of migraine associated with menstruation: results from an open-label postmarketing surveillance studyLawrence C Newman, Samira Harper, Beverly A Jones, et al.
Headache|July 17, 2015
Sumatriptan Iontophoretic Transdermal System Reduces Treatment-Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline - Results From a Randomized Controlled TrialMarcelo E Bigal, Richard B Lipton, Lawrence C Newman, et al.
Headache|September 2, 2017
Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive MedicinesJoshua M Cohen, David W Dodick, Ronghua Yang, et al.
Headache|May 22, 2021
Patient experience of telemedicine for headache care during the COVID-19 pandemic: An American Migraine Foundation survey studyChia-Chun Chiang, Rashmi Halker Singh, Nim Lalvani, et al.
Headache|October 4, 2025
Navigating the patient journey in migraine prevention: An American Migraine Foundation position paperLawrence C Newman, Christine Lay, Richard B Lipton, et al.
The Lancet. Neurology|October 4, 2015
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b studyMarcelo E Bigal, David W Dodick, Alan M Rapoport, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Neurology|October 26, 2005
Reversible anorgasmia with topiramate therapy for migraineLawrence C Newman, Susan W Broner, Christine L Lay
Headache|June 9, 2011
Migraine and vestibular symptoms--identifying clinical features that predict "vestibular migraine"Joshua M Cohen, Marcelo E Bigal, Lawrence C Newman
Journal of Women'S Health (2002)|July 25, 2009
Frovatriptan for acute treatment of migraine associated with menstruation: results from an open-label postmarketing surveillance studyLawrence C Newman, Samira Harper, Beverly A Jones, et al.
Headache|July 17, 2015
Sumatriptan Iontophoretic Transdermal System Reduces Treatment-Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline - Results From a Randomized Controlled TrialMarcelo E Bigal, Richard B Lipton, Lawrence C Newman, et al.
Headache|September 2, 2017
Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive MedicinesJoshua M Cohen, David W Dodick, Ronghua Yang, et al.
Headache|May 22, 2021
Patient experience of telemedicine for headache care during the COVID-19 pandemic: An American Migraine Foundation survey studyChia-Chun Chiang, Rashmi Halker Singh, Nim Lalvani, et al.
Headache|October 4, 2025
Navigating the patient journey in migraine prevention: An American Migraine Foundation position paperLawrence C Newman, Christine Lay, Richard B Lipton, et al.
The Lancet. Neurology|October 4, 2015
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b studyMarcelo E Bigal, David W Dodick, Alan M Rapoport, et al.
Pageof 2